| Zogenix Announces Success With DosePro |
| Monday, June 30, 2008 5:02:00 AM PDT | VentureDeal Staff |
San Diego, California -- Specialty pharmaceutical company Zogenix announced that it will present successful results from clinical studies of its product for the treatment of acute migraine and cluster headaches.
The product, DosePro, is a novel technology that allows patients to receive sumatriptan via the skin into a subcutaneous space without a needle.
The studies showed that maximum concentrations of the drug and delivery technology were reached within 12 minutes and that 98% of the patients were able to correctly use the new delivery technology on their first try, even in the midst of an acute migraine headache attack.
|
|
 Email Page |  Print Page
|
|
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
|
 |
|
|
 |